Neuromodulation as an Anti-inflammatory Treatment in SCI

NARecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 1, 2024

Primary Completion Date

August 30, 2024

Study Completion Date

August 31, 2024

Conditions
Spinal Cord InjuriesInflammation
Interventions
DEVICE

Transcutaneous auricular vagus nerve stimulation

Stimulation will target the auricular branch of the vagus nerve by applying stimulation to the cymba conchae region of the ear using the NEMOS® taVNS device (taVNS Technologies, Erlangen, Germany). To achieve adequate stimulation while avoiding unpleasant or painful sensations, the stimulation intensity will be gradually increased in increments of 0.1mA until the subjective pain threshold is reached, and then reduced to a stimulus intensity just below the individuals pain threshold (expected range based on prior studies 1 - 3.2mA(3). Pulse width will be set at 100μs and frequency will be set at 25Hz as performed in a previous protocol in stroke patients(3). The control group will receive the same stimulation parameters but will have the earpiece placed in the sham position such that stimulation is applied to the earlobe and does not activate the vagus nerve(4).

Trial Locations (1)

N6C 0A7

RECRUITING

Parkwood Institute, St Joseph's Health Care London, London

All Listed Sponsors
lead

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

OTHER